Dopaminergic and Metabolic Correlations With Cognitive Domains in Non-demented Parkinson’s Disease

Liang, Han; Lu, Jiaying; Tang, Yilin; Fan, Yun; Chen, Qi-Si; Li, Ling; Liu, Fengtao; Wang, Jian; Zuo, Chuantao; Zhao, Jue

doi:10.3389/fnagi.2021.627356

Cited by 12 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior works have also focused on the association between cognitive impairment and PET on dopaminergic (DAergic) molecular, glucose metabolism, and cholinergic molecular interactions. Several studies have suggested that PD-MCI has DAergic deficits in the striatum and the insula, while such defects in the PDD are in the striatum, anterior cingulate, and midbrain ( Chou et al, 2014 ; Aarsland et al, 2017 ; Politis et al, 2017 ; Han et al, 2021 ). It was reported that [C-11]-PE2I (N-(3-iodoprop-2E-enyl)-2b-carbomethoxy-3b-(4-methyl-phenyl)nortropane) (PE2I), a PET radiotracer targeting neuronal dopamine (DA) transporters with high specificity, avidity in the caudate, putamen, and pallidum was indicative of more severe cognitive function deficits ( Ivanidze et al, 2020 ).…”

Section: Clinical Features Of Parkinson’s Disease Mild Cognitive Impairment and Parkinson’s Disease’s Disease Dementiamentioning

confidence: 99%

Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

Fan

Han

Zhao

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is the second most common neurodegenerative disease. Cognitive impairment is one of the key non-motor symptoms of PD, affecting both mortality and quality of life. However, there are few experimental studies on the pathology and treatments of PD with mild cognitive impairment (PD-MCI) and PD dementia (PDD) due to the lack of representative models. To identify new strategies for developing representative models, we systematically summarized previous studies on PD-MCI and PDD and compared differences between existing models and diseases. Our initial search identified 5432 articles, of which 738 were duplicates. A total of 227 articles met our inclusion criteria and were included in the analysis. Models fell into three categories based on model design: neurotoxin-induced, transgenic, and combined. Although the neurotoxin-induced experimental model was the most common type that was used during every time period, transgenic and combined experimental models have gained significant recent attention. Unfortunately, there remains a big gap between ideal and actual experimental models. While each model has its own disadvantages, there have been tremendous advances in the development of PD models of cognitive impairment, and almost every model can verify a hypothesis about PD-MCI or PDD. Finally, our proposed strategies for developing novel models are as follows: a set of plans that integrate symptoms, biochemistry, neuroimaging, and other objective indicators to judge and identify that the novel model plays a key role in new strategies for developing representative models; novel models should simulate different clinical features of PD-MCI or PDD; inducible α-Syn overexpression and SH-SY5Y-A53T cellular models are good candidate models of PD-MCI or PDD.

show abstract

Section: Clinical Features Of Parkinson’s Disease Mild Cognitive Impairment and Parkinson’s Disease’s Disease Dementiamentioning

confidence: 99%

Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

Fan

Han

Zhao

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…A similar association between executive function and (right) DLPFC and medial frontal metabolism has been reported in a SPECT study of patients with MSA-P [7]. Our data, however, suggest a greater contribution of DLPFC function to executive performance in PD than in MSA-P. Stroop interference test performance was also correlated with white matter integrity along tracts between the striatum and the left inferior frontal gyrus in PD, but not MSA-P. Interestingly, in a recent PET study in PD patients by Han and colleagues, executive function was found to correlate with metabolism in the inferior frontal gyrus and additionally in the putamen and insula [34].…”

Section: Discussionmentioning

confidence: 91%

Structural and metabolic correlates of neuropsychological profiles in multiple system atrophy and Parkinson's disease

Kübler¹,

Kobylecki²,

McDonald³

et al. 2023

Parkinsonism & Related Disorders

View full text Add to dashboard Cite

“…Executive dysfunctions, already present in a considerable fraction of newly diagnosed patients ( Muslimović et al, 2005 ), may stem from dopamine deficits that affect fronto-striatal loops, while PD dementia that emerges in later PD stages could be caused by the impairment of other neurotransmitter signaling ( Kehagia et al, 2010 ). Although neuroimaging evidence points to the dopaminergic origins of executive dysfunctions in PD ( Han et al, 2021 ), the correlation of their severity with cardinal motor symptoms, also dependent on dopamine signaling, gives mixed results between the studies ( Campos-Sousa et al, 2010 ; Murakami et al, 2013 ; Schneider et al, 2015 ). Moreover, the incidence of depression was significantly increased in the prodromal phase of PD and was correlated with altered hyperechogenicity of the substantia nigra ( Walter et al, 2007 ), which again points to altered dopaminergic transmission as a potential cause.…”

Section: Introductionmentioning

confidence: 99%

Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson’s disease

Radlicka-Borysewska,

Jabłońska,

Lenarczyk

et al. 2024

Front. Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is characterized by three main motor symptoms: bradykinesia, rigidity and tremor. PD is also associated with diverse non-motor symptoms that may develop in parallel or precede motor dysfunctions, ranging from autonomic system dysfunctions and impaired sensory perception to cognitive deficits and depression. Here, we examine the role of the progressive loss of dopaminergic transmission in behaviors related to the non-motor symptoms of PD in a mouse model of the disease (the TIF-IADATCreERT2 strain). We found that in the period from 5 to 12 weeks after the induction of a gradual loss of dopaminergic neurons, mild motor symptoms became detectable, including changes in the distance between paws while standing as well as the swing speed and step sequence. Male mutant mice showed no apparent changes in olfactory acuity, no anhedonia-like behaviors, and normal learning in an instrumental task; however, a pronounced increase in the number of operant responses performed was noted. Similarly, female mice with progressive dopaminergic neuron degeneration showed normal learning in the probabilistic reversal learning task and no loss of sweet-taste preference, but again, a robustly higher number of choices were performed in the task. In both males and females, the higher number of instrumental responses did not affect the accuracy or the fraction of rewarded responses. Taken together, these data reveal discrete, dopamine-dependent non-motor symptoms that emerge in the early stages of dopaminergic neuron degeneration.

show abstract

Dopaminergic and Metabolic Correlations With Cognitive Domains in Non-demented Parkinson’s Disease

Cited by 12 publications

References 46 publications

Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

Experimental Models of Cognitive Impairment for Use in Parkinson’s Disease Research: The Distance Between Reality and Ideal

Structural and metabolic correlates of neuropsychological profiles in multiple system atrophy and Parkinson's disease

Non-motor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson’s disease

Contact Info

Product

Resources

About